Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maraviroc for GVHD Prophylaxis in RIC Allo-SCT
NCT01785810Phase 2Completed
- Sponsor
- Abramson Cancer Center
- Start
- Feb 2013
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of maraviroc in graft-versus-host disease (GVHD), sponsored by Abramson Cancer Center. Primary endpoint: Cumulative Incidence of Grade 2-4 Acute GVHD at 180 days. Started Feb 2013; status: completed.
02
Drugs
maraviroc
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT01785810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01785810.